Radiation and immune checkpoint inhibitors in the treatment of oligometastatic non-small-cell lung cancer: a practical review of rationale, recent data, and research questions.
Journal Information
Full Title: Ther Adv Med Oncol
Abbreviation: Ther Adv Med Oncol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Dr. Louie has received honoraria from AstraZeneca, unrelated to this review. Dr. Breadner has honoraria from Astra Zeneca, Bristol Myers Squibb, Takeda, Merck, and Amgen, unrelated to this review."
Funding Disclosure
Evidence found in paper:
"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025